The recommendation builds on the committee’s June 2024 vote for the use of RSV vaccines for people aged 60-74 at high risk. Credit: MargJohnsonVA/Shutterstock. · Pharmaceutical Technology · ...

Sanofi has joined a growing list of drugmakers going after alpha-synuclein targeting drugs for Parkinson's disease, licensing a bispecific antibody from South Korea's ABL Bio in a deal that could ...

Neuroscience isn't listed as one of the top R&D priorities at GSK, but a new alliance with ABL Bio adds to the sense that its focus may be shifting. The importance of biosimilars only continues to ...

including the US, Japan and Europe. ABL Bio previously entered into a global licensing agreement with GSK to develop treatments for neurodegenerative diseases.

Read Our Latest Stock Report on Bio-Rad Laboratories Bio-Rad Laboratories Stock Performance BIO opened at $245.23 on Wednesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 6 ...

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through ...

"We're excited to present Vitalgen's latest breakthroughs in gene therapy at BIO 2025," said Dr. Wu. "Our progress, particularly in the Parkinson's disease program, demonstrates the potential of our ...

Attovia Therapeutics has completed an oversubscribed $90 million Series C financing, which the company plans to use along with existing cash and investments to advance its two lead pipeline ...

ANN ARBOR, Mich., April 15, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology 1, today announced the ...